← Back to Search

SCFA Prodrug

tributyrin for Parkinson's Disease (BUTTER Trial)

Phase 1
Waitlist Available
Led By Nicolaas I Bohnen, MD, PhD
Research Sponsored by Nicolaas Bohnen, MD, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after approximately 30 days of intervention
Awards & highlights

BUTTER Trial Summary

This trial is testing whether a potential new therapy for Parkinson's disease, called tributyrin, is safe and effective.

BUTTER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after approximately 30 days of intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and after approximately 30 days of intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
glucose metabolism
Secondary outcome measures
FDG glucose PET brain
Montreal Cognitive Assessment cognitive rating scale (MoCa)
Brain

BUTTER Trial Design

2Treatment groups
Experimental Treatment
Group I: Parkinson's Disease Tributyrin InterventionExperimental Treatment1 Intervention
Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Group II: Healthy Control Tributyrin InterventionExperimental Treatment1 Intervention
Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tributyrin
Not yet FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Nicolaas Bohnen, MD, PhDLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
Nicolaas I Bohnen, MD, PhDPrincipal InvestigatorUniversity of Michigan
2 Previous Clinical Trials
70 Total Patients Enrolled

Media Library

Tributyrin (SCFA Prodrug) Clinical Trial Eligibility Overview. Trial Name: NCT05446168 — Phase 1
Parkinson's Disease Research Study Groups: Parkinson's Disease Tributyrin Intervention, Healthy Control Tributyrin Intervention
Parkinson's Disease Clinical Trial 2023: Tributyrin Highlights & Side Effects. Trial Name: NCT05446168 — Phase 1
Tributyrin (SCFA Prodrug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05446168 — Phase 1
Parkinson's Disease Patient Testimony for trial: Trial Name: NCT05446168 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What perils are associated with tributyrin consumption?

"As this trial is in its first phase, the safety of tributyrin has been rated as a 1 due to limited evidence regarding both efficacy and security."

Answered by AI

What is the magnitude of this trial's participant pool?

"Affirmative. Clinicaltrials.gov indicates that this medical experiment, initiated on July 1st 2022, is still actively recruiting participants. Only 20 individuals need to be enrolled at one single hospital centre."

Answered by AI

Are there any current opportunities to join this experimental protocol?

"According to clinicaltrials.gov, the research team is actively recruiting patients for this trial and has recently updated their posting from July 1st 2022 up until September 13th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Michigan
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

improve walking, better balance, urinary control.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
Nicolaas Bohnen, MD, PhD 2022. "Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05446168.
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top